Pavmed Inc C/Wts 30/04/2024(To Pur Com) Class Z News

Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization

TipRanksApr 15 05:16 ET

Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

TipRanksMar 29 07:46 ET

Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)

TipRanksMar 28 09:20 ET

Cantor Fitzgerald Reiterates Neutral on PAVmed, Maintains $1.4 Price Target

BenzingaAug 18, 2023 10:46 ET

PAVmed Analyst Ratings

BenzingaAug 18, 2023 10:45 ET

PAVmed (PAVM) Receives a Buy From Maxim Group

TipRanksAug 18, 2023 07:45 ET

Maxim Group Remains a Buy on PAVmed (PAVM)

TipRanksMay 18, 2023 15:35 ET

Ascendiant Sticks to Its Buy Rating for PAVmed (PAVM)

TipRanksApr 12, 2023 03:10 ET

Cantor Fitzgerald Downgrades PAVmed to Neutral From Overweight, Cuts Price Target to $1.50 From $4

MT NewswiresJan 20, 2023 08:38 ET

PAVmed Analyst Ratings

Benzinga Analyst RatingsJan 20, 2023 07:44 ET

Lake Street Adjusts PAVmed's Price Target to $1.50 From $5, Maintains Buy Rating

MT NewswiresJan 18, 2023 20:58 ET

PAVmed Analyst Ratings

Benzinga Analyst RatingsJan 18, 2023 09:38 ET

Maxim Group Sticks to Their Buy Rating for PAVmed (PAVM)

TipRanksAug 18, 2022 07:45 ET

PAVmed Is Maintained at Buy by Lake Street

Dow JonesAug 17, 2022 10:42 ET

PAVmed Price Target Cut to $5.00/Share From $7.00 by Lake Street

Dow JonesAug 17, 2022 10:42 ET

PAVmed Analyst Ratings

Benzinga Analyst RatingsAug 17, 2022 10:34 ET

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $5

Benzinga Real-time NewsAug 17, 2022 10:34 ET